PDF(Pubmed)
Abstract：
Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.
摘要：
患有血液系统恶性肿瘤和过去的乙型肝炎血清学证据的患者有HBV再激活的风险。在骨髓增殖性肿瘤中，用JAK1/2抑制剂ruxolitinib持续治疗赋予中等的再激活风险(1-10%);然而,没有前瞻性随机数据可用于强烈建议在这些患者中预防HBV.这里,我们报告了一例原发性骨髓纤维化和HBV感染的血清学证据，用鲁索替尼和伴随的拉米夫定治疗，发展HBV再激活由于过早退出预防。该病例强调了在鲁索替尼治疗的设置中持续预防HBV的潜在需要。
